1. Home
  2. GRF vs NSRX Comparison

GRF vs NSRX Comparison

Compare GRF & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

HOLD

Current Price

$10.33

Market Cap

39.9M

Sector

Finance

ML Signal

HOLD

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$3.65

Market Cap

38.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRF
NSRX
Founded
1989
2019
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
38.9M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
GRF
NSRX
Price
$10.33
$3.65
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
4.0K
10.6K
Earning Date
01-01-0001
03-25-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
N/A
EPS
1.16
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.60
$1.98
52 Week High
$11.85
$9.50

Technical Indicators

Market Signals
Indicator
GRF
NSRX
Relative Strength Index (RSI) 49.09 48.24
Support Level $9.69 $2.90
Resistance Level $10.64 $3.60
Average True Range (ATR) 0.12 0.32
MACD -0.02 -0.07
Stochastic Oscillator 51.97 45.74

Price Performance

Historical Comparison
GRF
NSRX

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: